Local Excision After Preoperative Chemoradiotherapy for Rectal Cancer: Results of a Multicenter Phase II Clinical Trial
BACKGROUND:Transanal local excision has been suggested as an attractive approach for patients with rectal cancer who show a major clinical response after preoperative chemoradiotherapy. OBJECTIVE:To evaluate the impact of transanal local excision on the local recurrence of rectal cancer in patients...
Gespeichert in:
Veröffentlicht in: | Diseases of the colon & rectum 2013-12, Vol.56 (12), p.1349-1356 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BACKGROUND:Transanal local excision has been suggested as an attractive approach for patients with rectal cancer who show a major clinical response after preoperative chemoradiotherapy.
OBJECTIVE:To evaluate the impact of transanal local excision on the local recurrence of rectal cancer in patients who had a major clinical response after preoperative chemoradiotherapy.
DESIGN:Sequential 2-stage phase II study for early efficacy.
SETTING:Multicenter study.
PATIENTS:Patients with clinical T3 or low-lying T2 rectal adenocarcinoma that showed a major clinical response after a preoperative chemoradiotherapy. Eligible patients underwent a full-thickness transanal local excision. According to their histopathology, the patients staged as ypT0-1 were observed, while the remaining patients were recommended to undergo a subsequent total mesorectal excision.
MAIN OUTCOME MEASURES:A local recurrence rate of ≤5% was set as a successful rate for stopping the trial early after the first stage.
RESULTS:The study group included 63 patients. Before chemoradiotherapy, patients were staged as clinical T3 (n = 42) and T2 (n = 21). After the local excision, 43 patients fulfilled the criteria to be observed with no further treatment. Nine of the remaining 20 patients for whom a subsequent total mesorectal excision was recommended refused surgery. Two of these patients who refused surgery had intraluminal local recurrence; both had a ypT2 tumor and underwent salvage surgery. The estimated cumulative 3-year overall survival, disease-free survival and local disease-free survival were 91.5% (95% CI75.9–97.2), 91.0% (95% CI77.0–96.6) and 96.9% (95% CI80.3–99.5), respectively.
LIMITATIONS:The time of follow-up is still short and the sample size is limited.
CONCLUSIONS:Our data suggest that local excision is a good option for patients with a major clinical response after chemoradiotherapy. A longer period of follow-up is required to confirm these findings. |
---|---|
ISSN: | 0012-3706 1530-0358 |
DOI: | 10.1097/DCR.0b013e3182a2303e |